Pepti Tirzepatide Review: $179 Flat, and Two Prices for One Drug (2026)

Pepti sells injectable compounded tirzepatide at $179 per 28-day cycle, and says that price is the same at 2.5 mg and at 15 mg — no dose-indexed increase, cancel whenever you like. Dose-flat pricing is the single most valuable term a compounded GLP-1 seller can offer. Two things sit against it. Pepti's own cost page prints $149 for the same product every other surface prices at $179. And in August 2026 we found a second tirzepatide price ladder in Pepti's production data that says something else entirely. Every price below was re-read live on 1 September 2026.

The published tirzepatide price

Injectable tirzepatide is $179, injectable semaglutide $109, and the label above each is Pepti's own: `ALL-IN MONTHLY PRICE`. What that phrase does not say is that the cycle is 28 days, which Pepti's billing terms state outright and add that a 28-day cycle "can bill twice in the same calendar month". That is thirteen charges a year, not twelve — a difference of one full month's medication against a program billed on the calendar.

And two of its own cost pages disagree with everything else. `/cost/tirzepatide` prints `$149` under the heading `All doses — one flat price`; `/cost/semaglutide` prints `$79`. The transactable figures — product page, category grid and the intake assessment alike — are $179 and $109. If you arrive from a cost page, you are reading a number the checkout does not use.

There is now no other kind of plan: the three-supply prepay was withdrawn, and Pepti's billing terms say so in those words, with existing enrollments continuing until canceled. So there is no prepay-as-monthly trap to unpick — the only trap here is the calendar one. Cancellation takes effect at the end of the cycle.

The ladder we could not reconcile

Read in August 2026, and not re-opened on the September pass — so treat it as dated rather than current. Pepti's tirzepatide page shipped a server payload containing a `doseOptions` array pricing tirzepatide by dose:

Nothing rendered it. We searched every JavaScript chunk the site downloads for the code that would consume that array and found zero occurrences. Meanwhile the page itself stated, in as many words, that all doses share one flat price. The catalog object the page actually reads carried the flat figure, and so did the cross-sell surfaces.

So which one bills you? We do not know, and we are not going to guess. The checkout endpoint accepts POST only and returns 405 to anything else, so there was no way to get a price out of it without submitting a real intake. What we can say precisely is this: the rendered price is flat, several independent surfaces agree on it, and a per-dose ladder running to several times that number was sitting in the data the page was built from in August. A dead array is usually a stale artifact somebody forgot to delete. Usually.

What to do with that. Before you pay Pepti anything, get the price for your dose in writing, and get it in writing again when you titrate up. If the flat price is real, that costs you one email. If it is not, that email is the difference between $179 and the top of that ladder at 15 mg — and 15 mg is where most people who respond to tirzepatide end up. Our tirzepatide dosage chart shows how quickly the ladder climbs.

Thirty-six states became fifty-one

In August, Pepti published an enumerated list of 36 states on four surfaces against a terms-of-service claim of 50, and the enumerated list was the operative number. On 1 September the site read "Now serving all 50 states and Washington, D.C." — so the gap has closed upward, and the enumerated list is gone with it. Two oddities remain: the page's own counter labels 50 states plus D.C. as "51 states", and blood testing is stated as 50 jurisdictions against 51 for peptide therapy, with no explanation of which one you fall into.

When your card is charged

Same pattern, smaller stakes. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake. The refund policy is the operative document, so plan on being charged first and refunded — in five to ten business days — if you are turned down. Nothing is refundable once medication ships, and canceling mid-cycle is not prorated.

What else is on the shelf, and what to walk past

Forty prescription peptide products across injectables, oral drops, nasal sprays, recovery peptides, anti-aging peptides and a small hormone line. Three of them belong in a warning rather than a catalog: retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any jurisdiction, in any form — it is still in trials, and a compounded version of an unapproved investigational molecule is a category of risk distinct from compounded tirzepatide. We explain the difference in retatrutide vs tirzepatide. Whatever Pepti's tirzepatide is worth, none of those three should factor into it.

Who prescribes, and who compounds

Two prescribers are named with full biographies: Dr. Gene Lee, MD, family medicine, medical director, and Dr. Laeeq Butt, MD MBA, internal medicine, chief medical officer, with the states each is licensed in listed out. That is good disclosure with one hole in it — neither NPI is published, so neither registration can be checked against the national provider registry. The Edit publishes its medical director's NPI and it resolves; see The Edit for what that looks like when it is done fully.

One pharmacy is named, and only in one place. Pepti's Pharmacy Fulfillment Policy reads "Prescriptions are fulfilled by the following independent, licensed U.S. pharmacy partners" and then names Olympia — with no legal entity, no state and no address beside it, and on the same page a statement that the fulfilling pharmacy varies by patient and that partners may change. Everywhere else the site uses the standard "independent FDA-registered 503A or 503B compounding pharmacies" formulation, which tells a reader nothing. The corporate entity is pepti LLC at a Newark, Delaware address that is a well-known registered-agent suite rather than an operating site — common, and not itself damning, but it means the address on the terms page is not a place where anything happens.

One more thing sits oddly beside that. The homepage trust cluster still carries an `FDA CLEARED` badge, while the product pages state that compounded medications are not FDA-approved or FDA-cleared. Both are Pepti's own words, on Pepti's own site.

The regulatory screen

The trading name and the legal entity both returned zero company-column matches in the FDA's live warning-letter index in August 2026.² Worth noting what surrounds them: a bare search for "pepti" returns forty-five letters, several of them to peptide sellers that FDA has written to. Pepti is not among them. The screen carried a positive control that correctly returned a real February 2026 letter to an unrelated telehealth seller on every pass,³ so the zero is a finding rather than a broken query.

Brand versus compounded

Everything here is compounded. Compounded tirzepatide is pharmacy-made, is not an FDA-approved finished drug, and was not the product used in the trials that make the molecule worth taking. See is compounded tirzepatide still legal in 2026. The trial evidence itself — roughly 15% to 21% average body-weight loss over 72 weeks in SURMOUNT-1⁴, about 20% against semaglutide's 14% in SURMOUNT-5⁵ — belongs to the brand molecule at approved doses, and is laid out in our tirzepatide evidence guide.

The honest verdict

If $179 is the price, Pepti is one of the stronger tirzepatide offers in our ranking: flat at every dose, cancellable, no prepay left to trip over, named prescribers, a named pharmacy partner and a 50-state list. What stops it being simple is that Pepti prints two different prices for the same drug on its own site today, and printed a third ladder in its production data a month ago. Get your dose priced in writing before you pay, and again when you titrate. Then compare it against Trellis Vitality, which lists tirzepatide at $199 and publishes an ordinary rung table with nothing hiding behind it, and against the rest of the field in our tirzepatide price index and the ranked best tirzepatide providers ranking.